专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US5895745A Method of thawing cryopreserved cells 失效
标题翻译：解冻冷冻保存细胞的方法
公开(公告)号：US5895745A
公开(公告)日：1999-04-20
申请号：US719769
申请日：1996-09-25
申请人： Barbara A. Chandler , Kermit M. Borland , Shawn P. Cain , Claudy J-P. Mullon
发明人： Barbara A. Chandler , Kermit M. Borland , Shawn P. Cain , Claudy J-P. Mullon
IPC分类号： C12N5/06 , A01N1/02 , C12N5/00 , G01N31/00
CPC分类号： A01N1/0284 , A01N1/0221 , Y10T436/108331
摘要： The invention features a method of processing cryopreserved cells by thawing and equilibrating the cells at warm temperatures (e.g., between 30.degree. C. and 43.degree. C). Either the cell suspension in the cryoprotective medium is thawed to a temperature between 35.degree. C. and 43.degree. C. or the cryoprotective medium is equilibrated with a culture medium at a temperature between 35.degree. C. and 43.degree. C., or both steps are carried out at the warm temperatures. By thawing and equilibrating the cryopreserved cells at warm temperatures, the viability, (especially after 3 hours of culture), and metabolic activity (i.e., diazepam metabolism) of the cells can be improved over traditional cold cell processing (i.e., at temperatures of between 2.degree. C. and 8.degree. C.).
摘要翻译：本发明的特征在于通过在温暖的温度（例如30℃至43℃）下解冻和平衡细胞来处理冷冻保存的细胞的方法。将冷冻保护培养基中的细胞悬浮液解冻至35℃至43℃之间的温度，或将冷冻保护培养基在培养基中在35℃至43℃之间的温度下平衡，或两个步骤在温暖的温度下进行。通过在温暖的温度下融化和平衡冷冻保存的细胞，可以比传统的冷细胞处理（即，在两者之间的温度）之间改善细胞的存活力（特别是培养3小时）和代谢活性（即，地西泮代谢） 2℃和8℃）。

2. 发明授权

US06172180B2 Highly branched block copolymers 有权
标题翻译：高支化嵌段共聚物
公开(公告)号：US06172180B2
公开(公告)日：2001-01-09
申请号：US09140284
申请日：1998-08-25
申请人： Lawrence F. Hancock , Stephen M. Fagan , Claudy J.-P. Mullon
发明人： Lawrence F. Hancock , Stephen M. Fagan , Claudy J.-P. Mullon
IPC分类号： C08G7523
CPC分类号： C08G83/005 , C08G75/23 , C08G81/00 , C08G83/002 , C08L71/00 , C08L71/02
摘要： The present invention relates to a block copolymer containing 1-50 first polymer segments and 1-50 second polymer segments. Each first polymer segment has an average mole fraction of monomers possessing a branch point of 0.0001 to 1, whereas each second polymer segment has an average mole fraction of monomers possessing a branch point of 0 to 0.5. The average molecular weights range from 5-2,000 kDa for the first polymer segments, which constitute 5-95% by weight of the block copolymer. The average molecular weights also range from 5-2,000 kDa for the second polymer segments, which constitute 5-95% by weight of the block copolymer. The ratio of the average mole fraction of monomers possessing a branch point of the second polymer segments to that of the first polymer segments is 0 to 0.5. An example of such a copolymer has ethylene oxide or ethylene oxide/propylene oxide as the first polymer segment and polysulfone as the second polymer segment. This block copolymer can further be blended with a bulk polymer.
摘要翻译：本发明涉及含有1-50个第一聚合物链段和1-50个第二聚合物链段的嵌段共聚物。每个第一聚合物链段具有分支点为0.0001至1的单体的平均摩尔分数，而每个第二聚合物链段具有分支点为0至0.5的单体的平均摩尔分数。第一聚合物链段的平均分子量范围为5-2,000kDa，占嵌段共聚物重量的5-95％。对于第二聚合物链段，平均分子量也为5-2,000kDa，占嵌段共聚物重量的5-95％。具有第二聚合物链段的分支点的单体的平均摩尔分数与第一聚合物链段的平均摩尔分数之比为0至0.5。作为第二聚合物链段，这种共聚物的例子有环氧乙烷或环氧乙烷/环氧丙烷作为第一聚合物链段和聚砜。该嵌段共聚物可进一步与本体聚合物共混。

3. 发明授权

US5858642A Closed system for processing cells 失效
标题翻译：用于处理细胞的封闭系统
公开(公告)号：US5858642A
公开(公告)日：1999-01-12
申请号：US719770
申请日：1996-09-25
申请人： Shawn P. Cain , Timothy J. Perlman , Deborah J. Deane , Claudy J-P. Mullon
发明人： Shawn P. Cain , Timothy J. Perlman , Deborah J. Deane , Claudy J-P. Mullon
IPC分类号： A01N1/02 , C12N5/00
CPC分类号： A01N1/02 , A01N1/0205 , A61K35/12 , A61K35/14 , A61K35/30 , A61K35/32 , A61K35/39 , A61K35/407
摘要： The invention features a method of processing cells in a closed system that results in a suspension of cells in a transfer vessel containing a target number of cells. The number of cells in the closed vessel is determined from the cell concentration (i.e., the number of viable cells/mL) in the closed vessel and the total volume of the suspension in the closed vessel. The volume of the suspension in the closed vessel can be determined from the weight of the suspension and its density. In particular, the cells are preserved in a protective medium and are recovered substantially free of the protective medium in a closed vessel containing the known number of cells in a suspension.
摘要翻译：本发明的特征在于一种在闭合系统中处理细胞的方法，该方法导致细胞在含有目标细胞数的转运容器中的悬浮。封闭容器中的细胞数目由密闭容器中的细胞浓度（即活细胞数/ mL）和密闭容器中悬浮液的总体积确定。悬浮液在密闭容器中的体积可以根据悬浮液的重量及其密度来确定。特别地，将细胞保存在保护性介质中，并在包含悬浮液中已知数量的细胞的密闭容器中基本上不含保护性介质的回收。

4. 发明授权

US5232696A Reduction of low density lipoproteins in biological fluids 失效
标题翻译：减少生物流体中低密度脂蛋白
公开(公告)号：US5232696A
公开(公告)日：1993-08-03
申请号：US101262
申请日：1987-09-25
申请人： Robert S. Lees , Robert S. Langer, Jr. , Claudy J. P. Mullon , Hugh D. Conlon
发明人： Robert S. Lees , Robert S. Langer, Jr. , Claudy J. P. Mullon , Hugh D. Conlon
IPC分类号： A61K38/43 , A61K35/14 , A61K38/46 , A61M1/16 , A61M1/34 , A61M1/36 , A61P3/06 , C12N11/10
CPC分类号： A61K38/465 , A61M1/3687 , A61M1/1678 , A61M2202/046
摘要： A method and apparatus for reducing the levels of low density lipoproteins (LDL) in blood is disclosed. The LDL is contacted with an enzyme which modifies it in a manner such that the LDL is rapidly removed endogenously by the patients' own metabolic processes. The enzyme may be introduced into the patient by injection, transdermal transport, nasal insufflation and ingestion. Additionally, the enzyme may be contained in a reactor for both in vivo and extracorporeal use.
摘要翻译：公开了一种降低血液中低密度脂蛋白（LDL）水平的方法和装置。使LDL与以其使得LDL被患者自身的代谢过程内源性快速去除的方式接触的酶接触。可以通过注射，透皮转运，鼻吹入和摄取将酶引入患者。此外，酶可以包含在用于体内和体外使用的反应器中。

5. 发明授权

US5200181A Oral bilirubin therapy 失效
标题翻译：口服胆红素治疗
公开(公告)号：US5200181A
公开(公告)日：1993-04-06
申请号：US593345
申请日：1990-10-01
申请人： Paul J. Soltys , Claudy J. P. Mullon , Robert S. Langer
发明人： Paul J. Soltys , Claudy J. P. Mullon , Robert S. Langer
IPC分类号： A61K38/44 , A61K38/45
CPC分类号： A61K38/45 , A61K38/44 , A61K47/4823 , A61K47/48853 , A61K9/0053 , C12Y103/03005 , C12Y204/01017
摘要： Levels of bilirubin in mammalian serum are controlled by administering to the mammalian intestinal tract a substance (a "bilirubin deactivator") that converts unconjugated bilirubin into nontoxic, physiologically compatible products, thereby reducing reabsorption of unconjugated bilirubin in enterohepatic circulation. Useful bilirubin deactivators include those which specifically adsorb the bilirubin and are excreted, and "bilirubin conversion enzymes", i.e., enzymes that operate on the unconjugated bilirubin substrate to yield products that are physiologically compatible in that they are not reabsorbed, or, if reabsorbed, they are nontoxic in the blood stream.
摘要翻译：哺乳动物血清中的胆红素水平通过向哺乳动物肠道施用将未结合的胆红素转化为无毒的生理相容产物的物质（“胆红素失活剂”）来控制，从而减少未结合的胆红素在肠肝循环中的再吸收。有用的胆红素减活剂包括特异性吸附胆红素并被排泄的那些，以及“胆红素转化酶”，即在非共轭胆红素底物上操作以产生生理上相容的产物，因为它们不被再吸收，或者如果被再吸收，它们在血液中无毒。

6. 发明授权

US5178864A Lipoprotein removal by soluble enzymes 失效
标题翻译： LIPOPROTEIN可溶性酶除去
公开(公告)号：US5178864A
公开(公告)日：1993-01-12
申请号：US567261
申请日：1990-08-14
申请人： Robert S. Lees , Robert S. Langer, Jr. , Regine Labeque , Claudy J. P. Mullon
发明人： Robert S. Lees , Robert S. Langer, Jr. , Regine Labeque , Claudy J. P. Mullon
IPC分类号： A61K38/46 , A61P3/06
CPC分类号： A61K38/465
摘要： A therapeutically effective amount of soluble phospholipase A.sub.2 is administered into a subject for lowering the low density lipoproteins ("LDL") in the blood. Phospholipase A.sub.2 modifies the plasma LDL by hydrolyzing the phospholipids present in LDL. As a result, the modified LDL is rapidly removed from the bloodstream by the catabolic processes.

7. 发明授权

US6042909A Encapsulation device 失效
标题翻译：封装装置
公开(公告)号：US6042909A
公开(公告)日：2000-03-28
申请号：US922910
申请日：1997-09-03
申请人： Karen E. Dunleavy , Timothy J. Perlman , Kerry A. Gagnon , Claudy J. P. Mullon
发明人： Karen E. Dunleavy , Timothy J. Perlman , Kerry A. Gagnon , Claudy J. P. Mullon
IPC分类号： A61L27/54 , A61L31/16 , A61K9/22 , A61M31/00 , C12M1/00 , C12N5/00
CPC分类号： A61L31/16 , A61L27/54 , Y10S206/828 , Y10S424/07 , Y10T428/1352 , Y10T428/1379 , Y10T428/139 , Y10T428/24843 , Y10T428/2817 , Y10T428/2896
摘要： The invention features an empty device for receiving a bioactive agent. The device includes a biocompatible and semi-permeable membrane that defines an enclosed space; the membrane also has at least one end that defines an opening for introducing the bioactive agent into the enclosed space. The device is configured to be placed in an animal.In one embodiment of the invention, the membrane has an inner surface and an outer surface, where the inner surface defines the inner surface, and includes a biocompatible adhesive in the general region of the opening to allow sealing of the opening after the introduction of the bioactive agent into the enclosed space.Another embodiment of the invention includes a biocompatible frame mounted in supporting relationship to the membrane and defining an opening for introducing the bioactive agent into the enclosed space. The frame has greater porosity than the membrane.
摘要翻译：本发明具有用于接收生物活性剂的空装置。该装置包括限定封闭空间的生物相容性半透膜; 膜还具有限定用于将生物活性剂引入封闭空间的开口的至少一个端部。该装置被配置成放置在动物中。在本发明的一个实施例中，膜具有内表面和外表面，其中内表面限定内表面，并且在开口的一般区域中包括生物相容性粘合剂，以允许在引入开口之后密封开口生物活性剂进入封闭空间。本发明的另一个实施方案包括生物相容性框架，其以与膜的支撑关系安装并限定用于将生物活性剂引入封闭空间的开口。框架具有比膜更大的孔隙率。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式